Prostate-specific antigen: Critical issues for the practicing physician

H. C. Ruckle, G. G. Klee, J. E. Oesterling

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Background: Serum prostate-specific antigen (PSA), when used in combination with existing detection methods, improves the clinician's ability to detect early and potentially curable prostate cancer. Findings: This report describes clinically important issues about use of the serum PSA concentration for detecting early prostate cancer. Other PSA-related factors- PSA density, PSA velocity, and age-specific reference ranges-seem to enhance the ability of clinicians to distinguish benign prostatic conditions from early prostate cancer. Because digital rectal examination only minimally affects the serum PSA concentration, delaying a determination after this examination is unnecessary. Finasteride therapy for benign prostatic hyperplasia should be initiated only after the prostate has been evaluated for cancer because this 5α-reductase inhibitor lowers the serum PSA value by approximately 50%; however, reassessment of the prostate for cancer is necessary if the PSA level fails to decrease as expected or increases to more than 2 ng/mL during finasteride treatment. Conclusion: Currently, PSA is the most important, accurate, and clinically useful tumor marker for prostate cancer.

Original languageEnglish (US)
Pages (from-to)59-68
Number of pages10
JournalMayo Clinic Proceedings
Volume69
Issue number1
StatePublished - 1994

Fingerprint

Prostate-Specific Antigen
Physicians
Prostatic Neoplasms
Finasteride
Serum
Digital Rectal Examination
Prostatic Hyperplasia
Tumor Biomarkers
Prostate
Oxidoreductases
Reference Values
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Ruckle, H. C., Klee, G. G., & Oesterling, J. E. (1994). Prostate-specific antigen: Critical issues for the practicing physician. Mayo Clinic Proceedings, 69(1), 59-68.

Prostate-specific antigen : Critical issues for the practicing physician. / Ruckle, H. C.; Klee, G. G.; Oesterling, J. E.

In: Mayo Clinic Proceedings, Vol. 69, No. 1, 1994, p. 59-68.

Research output: Contribution to journalArticle

Ruckle, HC, Klee, GG & Oesterling, JE 1994, 'Prostate-specific antigen: Critical issues for the practicing physician', Mayo Clinic Proceedings, vol. 69, no. 1, pp. 59-68.
Ruckle, H. C. ; Klee, G. G. ; Oesterling, J. E. / Prostate-specific antigen : Critical issues for the practicing physician. In: Mayo Clinic Proceedings. 1994 ; Vol. 69, No. 1. pp. 59-68.
@article{cabb76a2e2824dbb9b000d3c4f0acd64,
title = "Prostate-specific antigen: Critical issues for the practicing physician",
abstract = "Background: Serum prostate-specific antigen (PSA), when used in combination with existing detection methods, improves the clinician's ability to detect early and potentially curable prostate cancer. Findings: This report describes clinically important issues about use of the serum PSA concentration for detecting early prostate cancer. Other PSA-related factors- PSA density, PSA velocity, and age-specific reference ranges-seem to enhance the ability of clinicians to distinguish benign prostatic conditions from early prostate cancer. Because digital rectal examination only minimally affects the serum PSA concentration, delaying a determination after this examination is unnecessary. Finasteride therapy for benign prostatic hyperplasia should be initiated only after the prostate has been evaluated for cancer because this 5α-reductase inhibitor lowers the serum PSA value by approximately 50{\%}; however, reassessment of the prostate for cancer is necessary if the PSA level fails to decrease as expected or increases to more than 2 ng/mL during finasteride treatment. Conclusion: Currently, PSA is the most important, accurate, and clinically useful tumor marker for prostate cancer.",
author = "Ruckle, {H. C.} and Klee, {G. G.} and Oesterling, {J. E.}",
year = "1994",
language = "English (US)",
volume = "69",
pages = "59--68",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "1",

}

TY - JOUR

T1 - Prostate-specific antigen

T2 - Critical issues for the practicing physician

AU - Ruckle, H. C.

AU - Klee, G. G.

AU - Oesterling, J. E.

PY - 1994

Y1 - 1994

N2 - Background: Serum prostate-specific antigen (PSA), when used in combination with existing detection methods, improves the clinician's ability to detect early and potentially curable prostate cancer. Findings: This report describes clinically important issues about use of the serum PSA concentration for detecting early prostate cancer. Other PSA-related factors- PSA density, PSA velocity, and age-specific reference ranges-seem to enhance the ability of clinicians to distinguish benign prostatic conditions from early prostate cancer. Because digital rectal examination only minimally affects the serum PSA concentration, delaying a determination after this examination is unnecessary. Finasteride therapy for benign prostatic hyperplasia should be initiated only after the prostate has been evaluated for cancer because this 5α-reductase inhibitor lowers the serum PSA value by approximately 50%; however, reassessment of the prostate for cancer is necessary if the PSA level fails to decrease as expected or increases to more than 2 ng/mL during finasteride treatment. Conclusion: Currently, PSA is the most important, accurate, and clinically useful tumor marker for prostate cancer.

AB - Background: Serum prostate-specific antigen (PSA), when used in combination with existing detection methods, improves the clinician's ability to detect early and potentially curable prostate cancer. Findings: This report describes clinically important issues about use of the serum PSA concentration for detecting early prostate cancer. Other PSA-related factors- PSA density, PSA velocity, and age-specific reference ranges-seem to enhance the ability of clinicians to distinguish benign prostatic conditions from early prostate cancer. Because digital rectal examination only minimally affects the serum PSA concentration, delaying a determination after this examination is unnecessary. Finasteride therapy for benign prostatic hyperplasia should be initiated only after the prostate has been evaluated for cancer because this 5α-reductase inhibitor lowers the serum PSA value by approximately 50%; however, reassessment of the prostate for cancer is necessary if the PSA level fails to decrease as expected or increases to more than 2 ng/mL during finasteride treatment. Conclusion: Currently, PSA is the most important, accurate, and clinically useful tumor marker for prostate cancer.

UR - http://www.scopus.com/inward/record.url?scp=0028045104&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028045104&partnerID=8YFLogxK

M3 - Article

C2 - 7505869

AN - SCOPUS:0028045104

VL - 69

SP - 59

EP - 68

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 1

ER -